Pharmaceuticals

Drug Development Drug Safety Weight Loss Drugs Weight Loss Clinical Trials Drug Pricing Medications Drug Approval Drug Regulation Prescription Drugs

REGENXBIO Investors Face April 14 Deadline to Seek Lead Role in Securities Suit

Plaintiffs tie losses to FDA trial holds disclosed Jan. 28 after a reported tumor in a participant.

Social Media Fuels Surge in Injectable Peptides, Prompting Safety Warnings

Report Says Complications Rose After FDA Allowed Mail-Order Abortion Pills

Lilly Urges Recall After Finding New Impurity in Compounded Tirzepatide With B12

Hawley Seeks to Revoke FDA Approval of Abortion Pill Mifepristone With New Senate Bill

FDA Warns Novo Nordisk Over Missed Reporting of Serious Semaglutide and GLP-1 Adverse Events

Brianna LaPaglia Warns Against Off-Label Ozempic Use in March 10 TikTok

Novo Nordisk Strikes Deal With Hims & Hers to Sell Wegovy and Ozempic, Drops Lawsuit

Eli Lilly to Invest $3 Billion in China to Build Orforglipron Manufacturing

Rhino Choco VIP 10X Recalled After FDA Finds Hidden Erectile Dysfunction Drug

EMA Backs Single-Dose Acoziborole for Gambiense Sleeping Sickness Outside EU

Lockout Supplements Recalls ‘Boner Bears’ Chocolate Syrup Nationwide After FDA Finds Undeclared Sildenafil

Novo Nordisk Licenses Vivtex Platform in $2.1 Billion Push for Oral Obesity and Diabetes Drugs

Gym-Goers Turn From Steroids to Peptide Injections

AbbVie to Invest $380 Million in Two North Chicago API Plants

Viking Therapeutics' Obesity Drug Moves Into Phase 3 as Investors Weigh Upside

Lilly Launches FDA-Cleared Monthly Zepbound KwikPen on LillyDirect at $299 Starter Price

New Single-Particle Assay Finds Disordered Lipid Nanoparticles Release RNA More Effectively

FDA Approves Vanda's Bysanti for Schizophrenia and Bipolar I in Adults

Lilly’s Taltz Plus Zepbound Outperforms Taltz Alone in Phase 3b Psoriasis-Obesity Trial